An observational study in Atopic Dermatitis and Psoriasis, sponsored by Prof. Dr. Stephan Weidinger. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-07-22.
Sponsored by Prof. Dr. Stephan Weidinger · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Dermatitis, Atopic with a site in Germany — 19 open to participants now, 42 under way, 9 of them phase 3. Dermatitis, Atopic · Germany.
Among the 230 studies in Dermatitis, Atopic with a site in Germany, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 11 that started in 2017, is one of 21 observational ones, reaches primary completion later than 32 of the 41 other live ones, and was the 90th registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →19 of the 230 studies in Dermatitis, Atopic with a site in Germany are open now. Recruiting first, the newest first:
Apollo Therapeutics Ltd · Sites in Germany, United States, Bulgaria and 5 more countries
Ages 18–65
Chong Kun Dang Pharmaceutical · Sites in Germany, United Kingdom
Ages 18–55 · Healthy volunteers
Pfizer · Sites in Germany, United States, Bulgaria and 6 more countries
Ages 18–64
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
Galderma R&D · Sites in Germany, United States, United Kingdom
Ages 12+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 86 · Phase 3 66 · Phase 4 11
First in 1998; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 195 across the 205 interventional studies, 634 across the 21 observational. Of the 184 that completed or were terminated, 95 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
195 of 230 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. Stephan Weidinger is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Prof. Dr. Stephan Weidinger has 3 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
15 of the studies in Dermatitis, Atopic with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT07230860Janssen Research & Development, LLCA Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | 2026-11-19 |
| NCT05099315Charite University, Berlin, GermanyMicrobiome in Atopic Dermatitis Under Systemic Therapy | 2026-12-31 |
| NCT03057860Technische Universität DresdenTREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 230 studies in Dermatitis, Atopic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.
This is an exploratory study with the aim to identify molecular profiles and signatures in skin and blood that correlate with inflammatory skin disease, disease activity and disease progression, and that are associated with possible disease subtypes/endotypes. Primary target variables are differentially expressed genes (alone or in combination), secondary target variables are genetic, immunological and microbiological signatures. Influencing variables of interest include age of manifestation, disease duration, disease activity/severity, disease progression, comorbidities and therapy/treatment. Obtained biomaterial will be used for molecular profiling including DNA/RNA sequencing, ELISA, mass spectrometry, flow cytometry to identify markers and/or signatures that can correlate with individual disease courses.
Patients with chronic inflammatory skin disease who receive systemic therapy from their treating dermatologist during routine care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pso\_Tumor Necrosis Factor (TNF) Inhibitors
Drug: Anti-TNF
Interleukin (IL)-12/23 Inhibitors
Drug: Anti-IL12/23
Pso\_Interleukin (IL)-17 Inhibitors
Drug: Anti-IL17
Dupilumab
Drug: Dupilumab
Brodalumab
Drug: Lebrikizumab
Tralokinumab
Drug: Tralokinumab
Baricitinib
Drug: Baricitinib
Abrocitinib
Drug: Abrocitinib
Upadacitinib
Drug: Upadacitinib
Interleukin (IL)-23 Inhibitors
Drug: Anti-IL23
Interleukin (IL)-31 Inhibitors
Drug: Nemolizumab
HS\_Interleukin (IL)-17 Inhibitors
Drug: Anti-IL17
HS\_Tumor Necrosis Factor (TNF) Inhibitors
Drug: Anti-TNF
Subject receives anti-TNF antibodies open-label as per guidelines
Drug page: Ustekinumab
Subject receives anti-IL12/23 antibodies open-label as per guidelines
Subject receives anti-IL17 antibodies open-label as per guidelines
Subject receives Dupilumab open-label as per guidelines
Subject receives anti-IL23 antibodies open-label as per guidelines
Subject receives Baricitinib open-label as per guidelines
Subject receives Abrocitinib open-label as per guidelines
Subject receives Upadacitinib open-label as per guidelines
Subject receives Tralokinumab open-label as per guidelines
Subject receives Lebrikizumab open-label as per guidelines
Subject receives Nemolizumab open-label as per guidelines
Changes of molecular profiles over time
Changes of immune cell composition, transcriptome, proteome and microbiome signatures
Time frame: Baseline and week 2, week 4, week 12, week 52
Changes of molecular profiles associated with disease severity/remission
Changes of immune cell composition, transcriptome, proteome and microbiome signatures
Time frame: Baseline and week 2, week 4, week 12, week 52
Changes of molecular profiles associated with treatment
Changes of immune cell composition, transcriptome, proteome and microbiome signatures
Time frame: Baseline and week 2, week 4, week 12, week 52
Changes of molecular profiles associated with treatment response
Changes of immune cell composition, transcriptome, proteome and microbiome signatures
Time frame: Baseline and week 2, week 4, week 12, week 52
Change in Eczema Area and Severity Index (EASI) score
Clinical severity score
Time frame: Baseline and week 1, week 2, week 12, week 52
Change in Score of Atopic Dermatitis (SCORAD)
Clinical severity score
Time frame: Baseline and week 1, week 2, week 12, week 52
Change in Psoriasis Area and Severity Index (PASI)
Clinical severity score
Time frame: Baseline and week 1, week 2, week 12, week 52
Change in Hidradenitis Suppurativa Severity Score (IHS4)
Clinical severity score
Time frame: Baseline and week 1, week 2, week 12, week 52
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for Dec 2028, 143 months after the start.
Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 143 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. Stephan Weidinger